Publications by authors named "İbrahim Petekkaya"

Background: The management of early rectal cancer is different from that of colon cancer in terms of radiotherapy (RT) requirements or neoadjuvant treatment. It is not clear how the course of rectal cancer differs from that of the colon in a metastatic setting or how it should be approached differently. This study aimed to evaluate outcomes after combining downsizing chemotherapy (CTx) with rescue surgery.

View Article and Find Full Text PDF
Article Synopsis
  • This study aims to explore how inflammatory markers impact prognosis in patients with metastatic breast cancer.
  • During the study, 81 patients were monitored, revealing that high levels of C-reactive protein, ferritin, and beta-2 microglobulin were linked to significantly shorter overall survival compared to those with normal levels.
  • The findings suggest that serum CRP, ferritin, and β2-M could serve as important indicators for predicting overall survival in metastatic breast cancer patients.
View Article and Find Full Text PDF

Background: There are insufficient predictive markers for renal cell carcinoma (RCC).

Methods: A total of 308 metastatic RCC patients were analyzed retrospectively.

Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.

View Article and Find Full Text PDF

Background: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC).

Methods: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013.

Results: Of 563 patients, 472 received adjuvant chemotherapy (CT) alone, chemoradiotherapy (CRT) alone, and chemoradiotherapy plus chemotherapy (CRT-CT) were analyzed.

View Article and Find Full Text PDF

Renal cell carcinoma (RCC) metastatic to the head and neck region is quite rare. This report describes a case of RCC metastatic to the oral tongue presenting initially with a renal mass that evaded diagnosis by biopsy examination of the primary lesion and was eventually established as a papillary type RCC by lingual biopsy examination. The tongue mass progressed rapidly despite chemotherapy with interferon-α2b, caused difficulties with oral food intake, and thus necessitated removal by partial glossectomy.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to evaluate the association between the rennin-angiotensin system (RAS) inhibition and the risk of breast cancer (BC) recurrence and progression in N3 positive patients.

Methods: The medical records of patients treated for N3 positive BC in Hacettepe Cancer Institute between 2005 and 2012 were evaluated. Angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis.

View Article and Find Full Text PDF

Purpose: To investigate the effect of inflammatory markers on the prognosis of patients with operable breast cancer.

Methods: This study was conducted on breast cancer patients followed up between December 2009 and December 2012 at the Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Medical School. A total of 704 patients with stages I to III disease whose inflammatory markers were assessed at the time of diagnosis were included the study.

View Article and Find Full Text PDF

Aims And Background: Breast cancer is a heterogeneous disease with various pathological and molecular subtypes. This study aims to determine the association between BMI and the distribution of breast cancer subtypes defined by estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2/neu) expression in pre- and postmenopausal breast cancers.

Methods And Study Design: A total of 1847 female breast cancer patients were involved.

View Article and Find Full Text PDF
Article Synopsis
  • Trastuzumab emtansine (T-DM1) is an advanced therapy for HER2-positive breast cancer, combining the targeted action of trastuzumab with a powerful cytotoxic agent, DM1, showing effectiveness even in resistant cancer cells.
  • Clinical studies, particularly the phase III EMILIA trial, demonstrated that T-DM1 leads to improved tumor response, progression-free survival, and overall survival compared to other treatments.
  • Ongoing trials such as MARIANNE and TH3RESA will provide more insights regarding T-DM1's role in both advanced and early-stage HER2-positive breast cancer treatment.
View Article and Find Full Text PDF

The air crescent sign is a well-known important diagnostic finding in invasive pulmonary aspergillosis. Herein we report a distinctive but rare ultrasonographic appearance in a patient with myositis secondary to Aspergillus flavus infection, which can be considered as the soft tissue counterpart of the air crescent sign.

View Article and Find Full Text PDF

Background: Breast cancer is the most commonly diagnosed cancer in women worldwide and characterized its by molecular and clinical heterogeneity. Gene expression profiling studies have classified breast cancers into five subtypes: luminal A, luminal B, HER-2 overexpressing, basal-like, and normal breast-like. Although clinical differences between subtypes have been well described in the literature, etiologic heterogeneity have not been fully studied.

View Article and Find Full Text PDF

Lapatinib is a dual tyrosine kinase inhibitor (TKI) that has a considerable efficacy in ErbB2-positive metastatic breast cancer (MBC). Previous studies revealed that TKIs caused cardiotoxicity in approximately 10 % of the patients. This study assessed the cardiac safety of lapatinib in women with ErbB2-positive MBC.

View Article and Find Full Text PDF